GABRG1 and schizophrenia: Given that glutamatergic/GABAergic/cholinergic synapses are essential for synaptic and neuronal functions, our finding suggests that potential therapy strategies via the receptors, NMDAR (GRIN1/GRIN3B), KA (GRIK4), and AMPA (GRIA4), involved in glutamatergic synapse pathway, CHRNA7 in cholinergic system, and GABAA (GABRG1/2), GABRD (GABRA4), GAT (SLC6A12), and GABAB (GABBR2) in GABAergic synaptic pathways, hold great promise to improve synaptic and neuronal dysfunctions including intellectual disability, cognitive deficits, autism, and schizophrenia in neurodegenerative diseases.